Immunity Enhancement in Immunocompromised Gastrointestinal Cancer Patients with Allogeneic Umbilical Cord Blood Mononuclear Cell Transfusion

Figure 2

Sequential changes of lymphocyte subsets with flow cytometry analysis. Pre-: before NMA; 4, 8, 12, 16, 24, 36, and 48 wks: after UCMC transfusion. (a) CD3+T cell; (b) CD3+CD4+T helper; (c) ratio of Treg/CD4+; (d) CD3+CD8+ cytotoxic T cell; (e) CD16+CD56+NK cell; (f) CD19+ B cell; (g) ratio of CD4+/CD8+. The reference range is depicted as that between the green dot lines; red solid line: UCMC transfusion; blue solid line: control group. Comparison between the trial and control groups, , .

(a)

(b)

(c)

(d)

(e)

(f)

(g)